Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 8,100 shares, a growth of 406.3% from the December 31st total of 1,600 shares. Based on an average trading volume of 356,600 shares, the short-interest ratio is presently 0.0 days.

Enzon Pharmaceuticals Trading Up 2.4 %

OTCMKTS:ENZN traded up $0.00 during trading hours on Thursday, hitting $0.13. 17,786 shares of the company were exchanged, compared to its average volume of 65,484. The stock has a market capitalization of $9.74 million, a price-to-earnings ratio of 13.14 and a beta of 0.27. Enzon Pharmaceuticals has a one year low of $0.06 and a one year high of $0.24. The company has a fifty day simple moving average of $0.13 and a 200 day simple moving average of $0.13.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.